In July, the EU approved RTS, S – a malaria vaccine also known by its trade name, Mosquirix – for use in children from six to 17 months old. While this is exciting news for everyone on the front line of the fight against the disease, many questions about the vaccine's deployment remain to be answered.
Oluwatosin Omole
Cap comentari:
Publica un comentari a l'entrada
Nota: Només un membre d'aquest blog pot publicar entrades.